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Abstract
Background: Telomerase controls telomere homeostasis and cell immortality and is a promising anti-cancer target, but few
small molecule telomerase inhibitors have been developed. Reactivated transcription of the catalytic subunit hTERT in
cancer cells controls telomerase expression. Better understanding of upstream pathways is critical for effective anti-
telomerase therapeutics and may reveal new targets to inhibit hTERT expression.
Methodology/Principal Findings: In a focused promoter screen, several GSK3 inhibitors suppressed hTERT reporter activity.
GSK3 inhibition using 6-bromoindirubin-39-oxime suppressed hTERT expression, telomerase activity and telomere length in
several cancer cell lines and growth and hTERT expression in ovarian cancer xenografts. Microarray analysis, network
modelling and oligonucleotide binding assays suggested that multiple transcription factors were affected. Extensive
remodelling involving Sp1, STAT3, c-Myc, NFkB, and p53 occurred at the endogenous hTERT promoter. RNAi screening of
the hTERT promoter revealed multiple kinase genes which affect the hTERT promoter, potentially acting through these
factors. Prolonged inhibitor treatments caused dynamic expression both of hTERT and of c-Jun, p53, STAT3, AR and c-Myc.
Conclusions/Significance: Our results indicate that GSK3 activates hTERT expression in cancer cells and contributes to
telomere length homeostasis. GSK3 inhibition is a clinical strategy for several chronic diseases. These results imply that it
may also be useful in cancer therapy. However, the complex network effects we show here have implications for either
setting.
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Introduction
Telomerase is a ribonucleoprotein reverse transcriptase which
counteracts telomere attrition in dividing cells by synthesising
telomere DNA [1]. Telomerase activity requires the catalytic
subunit hTERT and the RNA subunit hTERC, which contains the
template sequence for reverse transcription. Both gene products
are over-expressed in cancer cells relative to somatic cells and in
most human cancers. Telomere homeostasis is essential for cell
immortalisation and telomerase is an attractive anti-cancer target
[2].
Telomerase expression in cancer cells is dependent on aberrant
hTERC and hTERT transcription, resulting from multiple events
including altered signalling and changes in the promoter
chromatin environments relative to normal cells [3]. However,
the cloned promoters also have cancer cell specific activity, leading
many groups to develop telomerase-specific gene therapy models
[4]. Several transcription factors affecting each gene promoter are
known. The hTERT promoter, for example, is regulated by
multiple factors including Myc, Mad, Sp1, STATs, E2F and p53,
among others [5].
Current clinical trials of telomerase therapeutics include several
immunotherapeutics, an oncolytic adenovirus, and GRN163L, a
modified oligonucleotide telomerase inhibitor [2,5,6]. Targeting
telomerase transcription using signal transduction inhibitors may
also hold value [2,7]. However, signalling events upstream of the
telomerase genes remain poorly understood and in most studies in
which signal transduction inhibitors have been found to affect
expression of telomerase genes, long term treatments to examine
effects on telomere length and telomere dependent senescence
have not been performed. In this study, we tested whether focused
cell-based screening using well-defined kinase inhibitors could
provide a platform to identify new telomerase regulatory pathways
and candidate targets for pharmacological intervention.
We show that glycogen synthase kinase 3 (GSK3) activates
hTERT transcription and characterise the pathway upstream of
hTERT. GSK3 inhibition reduced hTERT promoter activity,
expression, telomerase activity and telomere lengths in several cell
lines and suppressed tumour growth and hTERT expression in a
xenograft model. Therefore, GSK3 inhibition may be an
appropriate anti-cancer strategy. Prolonged GSK3 inhibition in
A2780 cells profoundly reduced telomere lengths; interestingly
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however, hTERT expression was not stably suppressed but showed
dynamic oscillation.
GSK3a and b isoforms, which are both targets of GSK3
inhibitors, variously regulate diverse cellular processes including
survival and apoptosis, energy metabolism, cell fate specification
and stem cell self renewal through phosphorylation of multiple
substrates in several distinct pathways including Wnt and insulin
signalling [8,9]. We present a network model of hTERT activation
and show that GSK3 inhibition affects multiple transcription
factors converging on hTERT. Interestingly, expression levels of
several transcription factors were also dynamically regulated under
prolonged GSK3 inhibitor treatments, suggesting that GSK3 may
control steady state behaviour of the network. A whole-kinome
RNAi screen of the hTERT promoter is interpreted using this
model to predict rational combinatorial targets to enhance anti-
telomerase effects of GSK3 inhibitors.
Results
GSK3 activates the hTERT promoter
In a focused screen of 79 well characterised kinase inhibitors,
A2780 cells were transfected with hTERT reporter construct and
32 h post transfection were exposed to 10 mM each inhibitor for
16 h. Six compounds suppressed promoter activity by at least 2-
fold (figure 1A). Compounds 38 (Ro-31-8220, bis indole
maleimide family; 4.6-fold), 69 (indirubin-39-monoxime, indirubin
core; 2.2-fold) and 79 (kenpaullone, indolo benazepinone core;
11.1-fold) are all reported to inhibit GSK3 [10]. The other hit
compounds were: 26, tyrphostin AG 1295 (inhibitor of PDGFR
[11]); 50, 5-iodotubercidin (inhibitor of adenosine kinase [12]);
and 55, SU4312 (inhibitor of PDGFR and FGFR [13]).
To extend the observation that diverse GSK3 inhibitors
suppress hTERT promoter activity, we performed hTERT reporter
assays and parallel MTT assays, titrating the selective inhibitors
AR-A014418 (benzyl-thiazolyl urea substructure), TWS119 (pyr-
ollopyrimidine core), and 6-bromoindirubin-39-oxime (BIO,
indirubin core) alongside the GSK3-inactive BIO derivative 1-
methyl-BIO (MeBIO) [10]. Structures of all GSK3 inhibitors used
in this study are available in supporting figure S1. All supporting
figure and file legends are given in supporting file S4. Active
inhibitors of different chemotypes, but not MeBIO, suppressed
hTERT promoter activity at sub-toxic concentrations (figure 1B).
At optimal doses of 10 mM (AR-A01448) and 5 mM (TWS119 and
BIO) promoter activities were 62%, 67% and 55% of control. BIO
and MeBIO were also titrated against the hTERT reporter in
5637, C33A, A549 and HCT116 cells (figure 1C). BIO, but not
MeBIO, suppressed the hTERT promoter in all cells with IC50s in
the range 5.4 mM-8.2 mM. Similarly, BIO, but not MeBIO
activated Topflash reporter activity in all cells, indicative of
specific GSK3b inhibition (supporting figure S2).
To further characterise the effect of GSK3 on the hTERT
reporter we over-expressed mWnt3, mWnt5A or human DVL2 in
each cell line, which all inhibit GSK3b in Wnt signalling.
Additionally, we examined the effect of b-catenin over-expression.
Both Wnts and DVL2 reduced hTERT promoter activity in 5637,
HCT116 and A549. Wnt3 had the strongest effect and DVL2 the
weakest (figure 2A). Only mWnt3 had a significant effect in A2780
and the effect of mWnt5A was not significant in C33A. Promoter
repression was not correlated with basal b-catenin expression
(figure 2B). For example, despite low expression in A549 and
constitutively stable expression in HCT116, each construct had
similar effects, reducing promoter activity to 32% of control
(mWnt3), 8% (mWnt5A) and 14% (DVL2) in HCT116 and 33%,
8%, and 15%, respectively, in A549. Interestingly, wild type b-
catenin induced promoter activity in HCT116, A549 and C33A.
Supporting figure S3 shows the effect of each construct on
Topflash reporter activity in each cell line. b-catenin and DVL2
generally resulted in the strongest increase of Topflash activity,
whereas mWnt5A had a weaker effect. Interestingly, mWnt3
mildly decreased Topflash activity in some cells. The effect of each
transfection on canonical Wnt signalling presumably depends on
the specific status of the pathway in each cell type.
To confirm that GSK3b regulates the hTERT promoter, we co-
transfected each cell line with reporter and with 50 nM GSK3b-
specific siRNA (two GSK3b-specific siRNA were tested–siRNA-
203 and siRNA-42839). Both siRNAs tested reduced promoter
activity in all cells relative to non-specific control (Figure 2C). All
effects were significant except siRNA-42839 in 5637 cells.
Promoter activities ranged between 38%–75% of control for
siRNA-203 and 34%–83% for siRNA-42839 at 48 h post-
transfection. Both specific siRNAs produced a GSK3b knockdown
in A2780 at 50 nM (figure 2D). SiRNA-42839 produced a greater
knockdown than siRNA203 and, interestingly, also resulted in
some knockdown of GSK3a. The GSK3a transcript is highly
homologous with that of GSK3b in the 42839 target site, sharing
16/19 nucleotides. It is possible that GSK3a knockdown might
result from target sequence homology. However, given the high
nucleotide specificity of the RNAi mechanism, it is perhaps more
plausible that GSK3b affects GSK3a expression. Together these
data confirm that GSK3 activates the cloned hTERT promoter in
multiple cell lines.
Functional specificity of BIO
Specificity of the GSK3 inhibitor BIO was assessed by phospho-
specific multiplex western blotting. A2780 were treated with
DMSO, 5 mM BIO, or 10 mM roscovitine to control for inhibition
of possible off-target kinases CDK1, 2, and 5 [10]. Protein samples
from treated cells were separated by SDS-PAGE using single-well
10% Bis-Tris minigels and blotted onto PVDF filters. 28 individual
lanes were isolated on the filters using a miniblotter dual
apparatus. To provide a detailed view of effects on GSK3
signalling, each lane was probed with an individual antibody or
antibody cocktail to quantify expression (figure 3A) and phos-
phorylation (figure 3B) of multiple proteins involved in GSK3
signalling and other pathways. Intensity change of quantifiable
bands relative to control was assessed by densitometry. Note the
log scale in figure 3A.
BIO treatment strongly induced b-catenin (30.9-fold), cyclin D1
(8.2-fold) and glycogen synthase (GS) (6.3-fold), which are all
destabilised by GSK3 [14–16]. Expression of cyclins B1 and E2,
p90-RSK, STAT3, c-Jun and IkB were also increased by around
2–3 fold each. It has previously been reported that c-Jun and IkB
stability are also regulated by GSK3 [17,18]. Roscovitine also
mildly induced cyclin D1 (2.7-fold) but, in contrast with BIO,
decreased b-catenin (49% of control) and cyclin E2 (34%). As
previously reported, roscovitine induced MAPK phosphorylation
[19], while BIO blocked phosphorylation on AKT S473 (29% of
control), p90-RSK S380 (12%), STAT3 S727 (26%), and GS
(56%) and induced PP1a T320 phosphorylation (4.9-fold). Thus,
the effects of BIO are consistent with GSK3 inhibition and largely
non-overlapping with those of a pan-CDK inhibitor.
BIO inhibits endogenous telomerase
To determine whether GSK3 inhibition suppresses endogenous
telomerase, 5637, HCT116 and A2780 cells were cultured
continuously in log phase with BIO or DMSO given twice-weekly
for five weeks. Drug was not removed between treatments. Cells
were counted weekly and at each time point individual cell pellets
GSK3 Activates Telomerase
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Figure 1. GSK3 inhibitors suppress the hTERT promoter. (A) Kinase inhibitor screen: A2780 cells were transfected with hTERT-luciferase
reporter. 32 h later cells were treated for 16 h with DMSO or 10 mM kinase inhibitors prior to luciferase assay. Hits are shown outside the shaded area.
38: Ro-31-8220; 69: indirubin-39-monoxime; 79: kenpaullone. Mean of 3 experiments. (B) hTERT promoter inhibition and toxicity of GSK3 inhibitors.
A2780 cells were transfected with hTERT-luciferase reporter. 32 h later cells were treated for 16 h with compounds at 20 mM, 10 mM, 5 mM, 2.5 mM
and 1.25 mM or DMSO for 16 h prior to luciferase assay. Parallel MTT assays of compound toxicity were performed. Mean6SEM of 3 experiments. (C)
BIO suppresses the hTERT promoter in multiple cell lines. Cells were transfected with hTERT-luciferase reporter. 32 h later cells were treated for 16 h
with inhibitor titrations as in (B) prior to luciferase assay. Mean6SEM of 3 experiments.
doi:10.1371/journal.pone.0006459.g001
GSK3 Activates Telomerase
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were taken from both control and treated cells for telomere length
analysis, hTERT expression analysis by RT-QPCR, microarray
analysis, western blotting of GSK3 inhibition markers, and for
TRAP analysis of telomerase activity (figure 3C). At the time of
sampling, drug had not been replenished for 3 days. BIO
concentrations used in these experiments were 2.5 mM (A2780),
1 mM (HCT116) and 500 nM (5637).
Western blotting was performed to detect levels of b-catenin,
GSK3 and expression and phosphorylation of GS and PP1a at
each sampling time point (figure 3D). b-catenin is constitutively
stable in HCT116 but was also unaffected in the other cell lines,
presumably indicating rapid return to basal levels as the effects of
BIO diminish between treatment and sampling. However, GS
S641 phosphorylation decreased progressively in all BIO treated
cells and its expression was also increased throughout in A2780.
Therefore, GSK3 was inhibited in all cell lines. Additionally,
increased PP1a T320 phosphorylation and reduced GSK3a and b
expression were detected at all times in A2780 and HCT116.
Figure 2. GSK3b activates the hTERT promoter. (A) Wnt signalling inhibits the hTERT promoter. A2780 cells were transfected with hTERT-luciferase
and the CMV expression vectors shown. 48 h later reporter activities were determined relative to empty vector. Mean6SEM of 3 experiments (ns: not
significant; *: p,0.5; **: p,0.01). (B) Basal b-catenin expression in 20 mg protein samples was analysed by western blotting. The experiment was
performed twice. Representative blots are shown. (C) GSK3b RNAi inhibits the hTERT promoter. A2780 cells were transfected with hTERT-luciferase and
50 nM non-specific (NS) siRNA or GSK3b specific siRNAs 203 or 42839. 48 h later reporter activities were determined. Mean6SEM of 3 experiments (ns:
not significant; *: p,0.5; **: p,0.01). (D) Knockdown of GSK3b by siRNA-203 and -42839. A2780 were transfected with 50 nM siRNA and harvested after
48 h. 20 mg protein samples were analysed by western blotting. The experiment was performed twice. Representative blots are shown.
doi:10.1371/journal.pone.0006459.g002
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Figure 3. Specificity of BIO. A2780 cells were treated for 16 h with 5 mM BIO, 10 mM roscovitine, or DMSO. 1 mg protein samples were analysed by
multiplex western blotting to detect (A) expression and (B) phosphorylation of indicated proteins. Band intensity changes were assessed by
densitometry relative to DMSO. Phosphospecific bands are normalised with expression. Mean6SEM of 2 experiments. (C) BIO schedule in 5 week
treatments. Cells were treated twice weekly on days 1 and 4 with DMSO or BIO (A2780, 2.5 mM; HCT116, 1 mM; 5637, 500 nM). BIO was not removed
between treatments. Counting and harvesting was on treatment day 1 of each week. (D) GSK3 inhibition over 5 week BIO treatment. 20 mg protein
samples from each time point were analysed by western blotting (C, Control; B, BIO). Two independent treatments were analysed. Representative
blots are shown.
doi:10.1371/journal.pone.0006459.g003
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Prolonged telomerase inhibition is predicted to result in growth
plateau by analysis of cumulative population doublings (PD), but
this was not observed over five week BIO treatment, though
treated cells grew more slowly than controls (Figure 4A). Average
growth rates were around 7 PD/week (control) and 6 PD/week
(BIO) for 5637 and 8 PD/week (control) and 7 PD/week (BIO) for
HCT116. However, A2780 growth rates decreased under BIO
treatment. Controls grew steadily at approximately 8.5 PD/week,
whereas BIO treated cells had an initial rate of 8 PD/week,
slowing to ,7 PD by day 35.
RT-QPCR analysis confirmed that BIO suppressed hTERT
expression in all three cell lines (figure 4B). In A2780, hTERT
expression under BIO treatment was reduced to 25% of control on
day 28. Expression in treated HCT116 was 7% of control on day
28 and in 5637 was 24% of control on day 21. Analysis of hTERT
splice variants in A2780 cells revealed selective repression of the
full length transcript (supporting figure S4). We observed that
hTERT expression in BIO treated 5637 returned to control levels
on day 35. This observation is expanded below.
We next performed QPCR-TRAP analysis using the TRAPeze
XL kit to determine telomerase activity in control and treated
samples. Cell pellets from each time point were lysed in CHAPS
buffer and protein samples incubated with reaction mix containing
TS and RP primers in addition to the control K2 primer. Each
assay included no-telomerase, no-Taq, and heat-treated controls.
QPCR detection of fluorescein labelled RP product confirmed
that telomerase activity was reduced by BIO (figure 4C). TRAP
activity was reduced in all BIO treated cells by day 7 (A2780, 74%
of control; HCT116, 59%; 5637, 67%) and generally diminished
over the treatment, reaching 44% of control in A2780 on day 28,
then increasing slightly to 57% on day 35. In 5637, TRAP activity
rose on days 14 and 21, approaching control activity before
recommencing a downward trend to reach 71% by day 35, though
this reduction relative to control was not statistically significant.
HCT116 TRAP activity decreased continuously to 33% of control
levels by day 35.
Telomere lengths were reduced by BIO in all cell lines as
determined by telomere restriction fragment (TRF) analysis
(figure 4D). Genomic DNA was extracted from control and
treated cell pellets and digested with HinfI/RsaI. Digestion
products were separated by electrophoresis and analysed by
Southern blotting using a DIG-labelled telomere sequence probe
to determine telomere length range. The decreases were small and
were most evident at later time points, consistent with the short
treatment period. In HCT116 we also observed reduction of the
overall signal in treated samples. Therefore, GSK3 inhibition
suppresses hTERT expression, telomerase activity and decreases
telomere lengths in several cancer cell lines.
Network model of hTERT regulation
To characterise the mechanism of hTERT repression, we
performed microarray expression analysis using cDNA from day
21 control or BIO treated A2780. Three independent treatments
were analysed in duplicate. Mean intensity of 1048 differentially
expressed transcript IDs changed by .5-fold, p,0.01 between
control and treated cells across all repeats. Raw Agilent ID list with
fold intensity changes of the differentially expressed genes used for
modelling are available in supporting file S2. The full MIAME
compliant array data have been deposited for public access in the
Gene Expression Omnibus. The profile included multiple
transcriptional targets of Wnt signalling, such as uPAR, EphB,
Runx2, stromelysin, Irx3, Pitx2, Islet1, Tcf-1, LEF1, dickkopf-4,
axin-2, Wnt5B and Wnt11, consistent with ongoing inhibition of
GSK3 on treatment day 21.
Network modelling was performed on the profile using
MetaCore from Genego Inc [20]. 622 unique database objects
were recognised (note that several tags may correspond to a single
gene). We first identified networks centred on individual high-
degree transcription factor neighbours of differentially expressed
genes using the transcription-regulation algorithm (supporting
figure S5). All 144 unique genes from the ten highest scoring
networks were combined in an enriched list and a best-fit
transcriptional network was generated using the auto-expand
algorithm. Network size was optimised to include all differentially
expressed genes from the enriched list (23.2% of all input genes)
(supporting figure S6).
The analysis returned a network involving NFkB, ESR1,
STAT1, CREB1, c-Myc, p53 and AP-1 (figure 5A; blue and red
circles adjacent to network object icons represent fold intensity
change with values given in supporting file S3). Thus, altered
activity of these transcription factors may significantly contribute
to the observed BIO treatment profile. We therefore determined
shortest paths between GSK3 and these high-degree nodes using
the analyse-network algorithm (figure 5B). Interestingly, hTERT is
returned by this analysis as a high probability component of the
final network, defining a candidate network linking GSK3 and
telomerase. For clarity, only network objects downstream of GSK3
or upstream of hTERT are shown. The analysis suggests that
multiple transcription factors may participate in regulation of
hTERT by GSK3, including some or all of Sp1, E2F1, SMAD3,
STAT3, HIF-1a, Androgen Receptor (AR), p53, c-Myc, ESR1,
AP-1 and NFkB. All are reported to regulate hTERT or its cloned
promoter [5]. GSK3 inhibition may affect their activities both
directly and through several effectors.
Network validation
To validate the model, we first performed a multiplex consensus
oligonucleotide binding assay using the protein/DNA array I kit
from Panomics. 56 biotin-labelled double stranded consensus
transcription factor binding site probes were mixed with nuclear
extracts of A2780 treated for 16 h with DMSO or 5 mM BIO.
DNA-Protein complexes were bound to spin columns and
unbound probe washed off. Bound probes were then eluted and
hybridised to an unlabelled membrane array containing spots of
each consensus sequence. Hybridisation of labelled probes to the
membrane, indicative of binding to the nuclear extract, was
detected with strptavidin-HRP. Figure 5C shows densitometry of
quantifiable spots showing .1.5-fold intensity change in BIO
treated cells.
Signals for c-Myc, and Smad3/4 binding sequences were
reduced by 2.1-fold and 1.9-fold, respectively. Increased signal was
detected for NFkB (1.5-fold), p53 (2-fold), Sp1 (3.9-fold) and
STAT3 (3.9-fold) consensus sequences. HIF-1a was not repre-
sented on the array and we did not detect altered binding to
sequences for ESR1, AR, AP-1, or E2F1. However, longer
treatments may also affect these factors. Several other consensus
sequences also showed altered binding activity and their cognate
transcription factors may also participate in the overall effect of
GSK3 inhibition.
To validate the model with respect to hTERT, we performed
chromatin immunoprecipitation (ChIP) of Sp1, STAT3, p53, c-
Myc, and NFkB p65 in 16 h BIO or DMSO treated A2780.
QPCR detection of the hTERT promoter in precipitates revealed
widespread promoter remodelling, affecting both activators and
repressors (Figure 5D). Detectable immunoreactive epitopes of c-
Myc, p65 and p53 were reduced 2.9-fold, 4-fold and 2-fold
respectively, while that of STAT3 was increased 4.5-fold,
confirming that GSK3 inhibition rapidly affects the hTERT
GSK3 Activates Telomerase
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Figure 4. BIO inhibits telomerase. (A) 5 week cell growth curves under BIO treatment. Cells were counted weekly to determine cumulative
population doublings (PD). Mean6SEM of three experiments. (B) BIO represses hTERT expression. Control and treated samples from each time point
were analysed by Q-RTPCR for hTERT expression normalised to RPS15. Mean6SEM of hTERT expression in BIO treated cells relative to control from
three experiments (ns: not significant; **: p,0.01). (C) BIO represses telomerase activity. Telomerase activity was determined by Q-PCR TRAP analysis
in control or BIO treated cells. Mean6SEM of treated cells relative to controls from three experiments (ns: not significant; *: p,0.05; **: p,0.01). (D)
BIO shortens telomeres. 1 mg genomic DNA from control or treated cells was digested with HinfI/RsaI and southern blotted with DIG-labelled
telomere detection probe (C, Control; B, BIO; HMW and LMW, high and low molecular weight markers). Two independent treatments were analysed.
Representative blots are shown.
doi:10.1371/journal.pone.0006459.g004
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Figure 5. Network modelling and validation. (A) Transcriptional network of GSK3 inhibition. Differentially expressed genes from day 21 BIO
treated cells were identified using Agilent whole genome expression arrays (n = 3; mean fold change.5; p,0.01). High degree transcription factor
neighbours of differentially expressed genes were identified by network analysis in MetaCore. Blue circles: down-regulated in BIO treated cells; red
circles: up-regulated. Shading intensity indicates fold change (minimum 5-fold). Green arrows: activation; red: inhibition (reaction mechanisms not
shown). (B) Candidate network linking GSK3 to hTERT. Shortest paths linking transcription factors from (A) and GSK3 were identified in MetaCore.
Green arrows: activation; red: inhibition; reaction mechanisms not shown. (C) Multiplex consensus oligonucleotide binding in A2780 nuclear extracts.
16 h DMSO or BIO treated cell nuclear extracts were incubated with labelled consensus oligonucleotide probe mix prior to column purification and
hybridisation of eluted bound probes to oligonucleotide array. Mean6SEM of duplicate spots. (D) hTERT promoter remodelling. A2780 were treated
for 16 h with DMSO or 5 mM BIO prior to Chromatin IP (ChIP) with antibodies shown and QPCR detection of the hTERT promoter. Mean6SEM of three
experiments (ns: not significant; *: p,0.05; **: p,0.01).
doi:10.1371/journal.pone.0006459.g005
GSK3 Activates Telomerase
PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6459
promoter environment involving direct regulation by at least four
factors suggested by network analysis. Sp1 binding to the hTERT
promoter was unaffected by 16 h BIO treatment. Interestingly,
hTERT expression in 16 h BIO treated A2780 was not
significantly repressed and was even slightly increased, suggesting
that promoter remodelling may proceed dynamically in longer
treatments (supporting figure S7).
BIO inhibits hTERT expression and tumour growth in
xenografts
To determine whether GSK3 inhibition suppresses hTERT
expression in a tumour model, we inoculated A2780 into athymic
mice. BIO (2 mg/kg every second day or 6 mg/kg twice weekly)
or vehicle treatment was initiated via the intraperitoneal route
when mean tumour diameters reached ,0.5 cm. Tumours in
control animals took 7.8 days to increase five-fold in volume,
whereas the time taken was 13.1 days in the 2 mg/kg BIO group
and 16.9 days in the 6 mg/kg BIO group (figure 6A). No overt
toxicity was observed in treated groups. Therefore, BIO
suppressed growth of established A2780 xenografts.
Animals were sacrificed after 3 weeks treatment at 2 mg/kg or 4
weeks treatment at 6 mg/kg. Tumours were harvested for QPCR
analysis of hTERT expression (figure 6B). Median hTERT
expression of the control group is fixed at 100% (range 71.82%–
138.74%). BIO treatment suppressed hTERT expression to similar
levels in both treatment groups. Median expression in the 2 mg/kg
group was 58.62% that of the control group (range 39.85%–
95.55%) and 55.01% in the 6 mg/kg group (40.5%–95.33%). The
relative decrease in each treated group was statistically significant
as determined by the Mann-Whitney test (p = 0.026). Therefore,
GSK3 inhibition suppresses hTERT expression in established
A2780 xenografts.
Dynamic regulation of hTERT expression
To determine whether persistent inhibition of GSK3 results in
telomere dependent growth arrest in cancer cells, A2780 were
cultured in the presence of DMSO or 2.5 mM BIO for 25 weeks
with twice weekly dosing as in the schedule in figure 3. Cells were
counted weekly and analysis samples taken every four weeks. We
again examined markers of GSK3 inhibition by western blotting
(figure 6C). Because of decreasing growth rates, insufficient protein
was obtained in day 28 BIO treated cells. However, in earlier
experiments GSK3 was inhibited at this time point (figure 3D). As
previously observed, GS phosphorylation was suppressed, its
expression was increased and PP1a phosphorylation was also
elevated until day 140. However, on day 168, little differential was
observed between control and treated cells for GS expression or
PP1a phosphorylation.
To extend this observation we assessed levels of cyclin E2 which
increased after a single BIO dose (figure 3A). Cyclin E2 was
increased in treated cells on days 56, 84 and 140, but not days 112
or 168. Thus, cyclin E2 apparently oscillated in treated cells. In
contrast, GSK3 expression was reduced in treated cells at all time
points as in the earlier time course. Therefore, persistent exposure
to BIO had differential dynamic effects on downstream pathways.
To determine whether hTERT expression was suppressed
throughout the time course, we performed RT-QPCR
(figure 6D). Consistent with previous results, hTERT expression
was strongly repressed on day 28 in BIO treated cells (29% of
control). However, at subsequent time points until day 112,
hTERT suppression was less efficient. On day 112, coinciding with
the first loss of cyclin E2 induction, hTERT expression in treated
cells was not significantly different from controls, as observed for
5637 cells on treatment day 35. Thereafter, expression decreased
to a new low value on day 140 (10% of control) and remained at
12% of control on day 168. Thus, hTERT also appeared to
oscillate in treated cells.
TRF analysis showed that a substantial lag phase preceded
profound telomere shortening between days 112 and 140 in
treated A2780. Densitometric estimates of average length on day
140 were ,2 kb in treated cells, compared with ,5 kb in control
cells (Figure 6E). Therefore, persistent GSK3 inhibition signifi-
cantly reduced telomere length of ovarian cancer cells. However,
the blots also suggested that some extension occurred at days 112
and 168, which may be explained by the oscillation in hTERT
expression and/or other effects on telomerase mediated by
dynamic regulation of GSK3 effectors.
In these experiments, A2780 proliferation rapidly declined in
the first weeks of treatment, though full culture crisis was not
observed. While control cells grew steadily over the entire time
course at ,8.6 PD/week, growth of BIO treated cells decreased
from 8.2 PD/week at day 7 to 3.5 PD/week at day 35, causing a
partial growth plateau (figure 6F). Treated cells then grew at
3.5 PD/week until day 56, at which time growth accelerated,
reaching a rate of ,7 PD/week at day 126 which persisted for the
rest of the time course.
Network topology and dynamic behaviour
Although network modelling can successfully identify many of
the players in a pathway, predicting the outcome of manipulating
individual highly connected components of complex networks
such as figure 5B is a challenge. However, genetic networks are
mainly composed of recurring ‘‘wiring patterns’’ (network motifs)
which can be modelled or even synthetically constructed to
investigate relationships between motif topology and function [21].
Thus, identification of a network’s constituent motifs may help to
predict its behaviour. To better understand hTERT regulation by
GSK3, we searched for several previously described motif types in
the network model using MetaCore [21–23].
We identified multiple potential reciprocal repression (toggle
switch) and feedback oscillator motifs as in the examples in
figure 7A, which may provide substantial scope for dynamic
network behaviour. We also identified several types of coherent
feed forward motifs. In particular, three distinct sub-networks form
candidate activation and repression ‘‘modules’’. The activation
module links all positive regulators of hTERT via densely
overlapping coherent type 1 motifs, while the repression module
comprises several coherent type 2 motifs organised by p53 and AR
which inhibit hTERT and its activators. Both motif types are
reported to reduce noise in gene expression networks [21].
To further investigate the network structure, we determined the
presence of the MYC, RELA, and ESR1 gene promoters in the p53
ChIP experiments from figure 5D in which p53 binding to the
hTERT promoter was decreased. We found that 16 h BIO
treatment also reduced immunoreactive p53 at the MYC promoter
by 2.2-fold, by 3.6-fold at RELA and 5-fold at ESR1 (Figure 7B).
Therefore, the early outcome of BIO treatment with respect to
p53 includes co-ordinate regulation of the hTERT promoter and
the promoters of at least three of its activators also present in the
putative repression module sub-network.
Based on the proposed network topology, we hypothesised that
prolonged GSK3 inhibition might affect dynamic behaviour of
some transcription factors. Re-analysis of the 25 week time course
revealed complex, fluctuating expression patterns for c-Jun, p53, c-
Myc, AR and STAT3 expression, but not Sp1 or p65 in BIO
treated samples (figures 7C and D). AR, STAT3 and c-Jun each
showed a clear oscillation, particularly striking in the case of c-Jun,
with a trough occurring on day 112 for AR and STAT3 and on
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Figure 6. Therapeutic assessment of GSK inhibition. (A) Growth delay of A2780 xenografts. Athymic mice (n = 6/group) with established A2780
xenografts were treated intraperitoneally with BIO (2 mg/kg every two days, or 6 mg/kg twice weekly on days 1 and 4). Mean6SEM of calliper
estimated tumour volumes relative to treatment day 0. (B) hTERT expression in A2780 xenografts. Tumours from vehicle or treated animals were
excised and Q-RTPCR was performed. hTERT expression normalised to RPS15 in each tumour is shown. Bars show median expression (control = 100%).
(C) GSK3 inhibition during prolonged BIO treatment. A2780 cells were treated twice weekly on days 1 and 4 with 2.5 mM BIO or DMSO for 25 weeks.
Analysis samples were taken every 4 weeks on treatment day 1. 20 mg protein samples were analysed by western blotting. Two experiments were
analysed. Representative blots are shown. (D) Dynamic oscillation of hTERT expression. Control and treated samples from each time point were
analysed by Q-RTPCR for hTERT expression normalised to RPS15. Mean6SEM of hTERT expression relative to control from two experiments (ns: not
significant; *: p,0.5; **: p,0.01). (E) Prolonged BIO treatment shortens telomeres. 1 mg genomic DNA from control or treated cells was digested with
HinfI/RsaI and southern blotted with DIG-labelled telomere sequence probe. Two independent treatments were assessed. Representative blots are
shown. (F) Growth of A2780 cells during prolonged BIO treatment. Cells were counted weekly to determine cumulative population doublings (PD).
Mean6SEM of two experiments.
doi:10.1371/journal.pone.0006459.g006
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Figure 7. Network topology and dynamic behaviour. (A) Network motif analysis. Motifs in figure 5(B) were identified in MetaCore.
Representative examples are shown. Green arrows: positive regulation; red arrows: negative regulation (reaction mechanisms not shown). (B) BIO
regulates the repression module. A2780 were treated for 16 h with DMSO or 5 mM BIO prior to ChIP with p53 antibody and QPCR detection of
indicated promoters. Mean6SEM of three experiments (*: p,0.05; **: p,0.01). (C) Dynamic regulation of network transcription factor expression
levels under long term BIO treatment. Expression of network transcription factors in 20 mg protein samples from each time point of the 25 week time
course were analysed by western blotting (C, Control; B, BIO treatment). Two independent treatments were analysed. Representative blots are shown.
(D) Densitometry of (C): expression relative to control (c-Jun not shown due to scale). Mean6SEM of three measurements of each band. (E) Dynamic
regulation of hTERT and TP53 promoters by Sp1. A2780 were treated for 16 h with 5 mM BIO or 21 days with 2.5 mM prior to ChIP with Sp1 antibody
and QPCR detection of the hTERT and TP53 promoters. Mean6SEM of three experiments (ns: not significant; *: p,0.5; **: p,0.01).
doi:10.1371/journal.pone.0006459.g007
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day 140 for c-Jun. Levels of p53 were induced by BIO on days 56
and 84 but were lower than control at all other times. A similar,
though less pronounced result was observed for c-Myc. Therefore,
at least 5 transcription factors known to affect hTERT are subject
to dynamic regulation under persistent GSK3 inhibition.
Since Sp1 levels were unaffected, we assessed whether its activity
might be dynamically affected under prolonged GSK3 inhibition by
ChIP in A2780 after 21 day 2.5 mM BIO treatments. Recovery of
both hTERT and TP53 promoters were analysed and compared
with recovery after 16 h treatments. In contrast with the results after
16 h, immunoreactive Sp1 levels at the hTERT promoter were
increased by 3.7-fold after 21 days treatment. Furthermore, Sp1
epitope at the TP53 promoter was also increased by 1.6-fold at day
21. These data confirm that Sp1 is also dynamically regulated and
participates in ongoing remodelling of both hTERT and TP53
promoters under persistent GSK3 inhibition.
Whole kinome siRNA screen of the hTERT promoter
Finally, to enable rational prediction of hTERT regulatory
pathways overlapping with GSK3, we performed a whole kinome
siRNA screen using the hTERT reporter in A2780. 3 independent
siRNA against each of 719 kinase and kinase-related genes were
assessed. Hit criterion was .2-fold change in promoter activity by
at least 2/3 siRNA. A complex network of kinases controls activity
of the transfected hTERT promoter, with 235/719 target genes in
total scoring as hits. 232 were activators of the promoter
(repression by siRNA) and only 3 were repressors.
We searched MetaCore for direct phosphorylation interactions
between hits and network transcription factors (figure 8A; blue
circles represent mean fold promoter repression with hTERT
promoter activity values for each network target given in figure 8B).
At least 54 hit kinases participate in upstream pathways and 38
hits directly phosphorylate one or more of the transcription
factors. Critical divergence hubs with respect to the network
transcription factors are GSK3 itself, p90-RSK, several PKC
isoforms, PKA, JNK and p38. These hubs are predicted to be
important modifiers of hTERT suppression with GSK3 inhibitors
and preferred targets for combinatorial inhibition.
Discussion
In this study we show that GSK3 activates hTERT gene
expression and regulates telomere length homeostasis. We
identified GSK3 as a potential pharmacological target to inhibit
hTERT expression in a promoter screen of well defined kinase
inhibitors. The result was confirmed using independent selective
inhibitors of different chemotypes. BIO, GSK3b-specific siRNA,
and genetic agonists of Wnt signalling all suppressed hTERT
promoter activity in five cancer cell lines. Interestingly, over-
expression of b-catenin increased promoter activity, suggesting a
possible dual effect of Wnts on the hTERT promoter mediated by
both canonical and non-canonical pathways. Regulation of
endogenous hTERT by Wnts was not assessed in this study,
though Wnt5A was previously shown to suppress telomerase in
renal carcinoma cells [24]. Telomerase suppression by GSK3
inhibitors may partly involve Wnt pathways, but presumably also
involves other GSK3 activities.
Multiplex phospho-specific western analysis in BIO treated A2780
revealed a complex functional signature involving altered expression
of b-catenin, cyclins D1, B1 and E2, GS, as well as p90-RSK, STAT3
and IkB. Additionally, altered phosphorylation of AKT, p90-RSK,
PP1a, cdc2 and STAT3 were observed. Observation of several
markers over five weeks continuous treatment confirmed that GSK3
could be inhibited over prolonged periods.
Most importantly, BIO suppressed hTERT expression and
telomerase activity with resultant telomere shortening over five
weeks treatment in three cancer cell lines, indicating that a
promoter screening approach can identify bona fide telomerase
inhibitors. Microarray and network analysis of GSK3 inhibited
A2780 suggested that the activities of multiple transcription factors
could be altered. We defined a candidate network linking GSK3
and hTERT via some or all of Sp1, E2F1, STAT3, SMAD3,
ESR1, AR, HIF-1a, NFkb, AP-1, p53 and c-Myc.
In support of the network model, 16 h BIO treatment altered
binding affinity of A2780 nuclear extracts to multiple consensus
oligonucleotides, including sites for c-Myc, NFkB, SMAD3, p53,
Sp1 and STAT3. Critically, ChIP analysis indicated that
immunoreactive c-Myc, p53 and NFkB p65 were reduced at the
endogenous hTERT promoter by 16 h BIO treatment while
STAT3 was increased. It should be noted that ChIP results may
reflect changes either in DNA binding or in epitope masking. In
either case, GSK3 inhibition causes rapid and widespread
remodelling of the hTERT promoter involving at least these
factors and possibly others suggested by the network and oligo
binding analyses. Both activators and repressors of hTERT were
affected, underscoring the difficulty of interpreting the transcrip-
tional effect in terms of single factors.
GSK3 regulates several transcription factors directly and
effectors PTEN, b-catenin, p21, FAK1, Tuberin, cyclin D1 and
cyclin D2 may also play a role. We have not directly addressed
their roles in this study, though FAK1 siRNA suppressed the
hTERT promoter in A2780 and b-catenin over-expression up-
regulated the promoter in several cell lines. Furthermore, BIO
increased expression of b-catenin and cyclin D1 in A2780 cells and
reduced AKT phosphorylation which may occur downstream of
PTEN [25]. Previous studies have shown regulation of hTERT
and/or telomerase in various experimental settings by several of
these factors [26,27].
Consequently, GSK3 may control hTERT expression in a broad
range of cells, including those with mutation or disruption in one
or more branches of the network as in 5637 (mutant p53) or
HCT116 (mutant b-catenin). Thus, GSK3 could be an attractive
pharmacological target for broad spectrum suppression of
telomerase in cancer cells. In support of a therapeutic application,
BIO caused tumour growth delay and inhibited endogenous
hTERT expression in established A2780 xenografts without overt
toxicity. Unexpectedly, however, prolonged inhibition of GSK3 in
cultured A2780 did not lead to stable hTERT suppression,
although telomere lengths were profoundly reduced. Rather,
dynamic oscillation of hTERT was observed.
Complex inter-transcription factor interactions are expected
from the model. Upstream of hTERT are multiple densely
overlapping coherent type 1 feed-forward motifs mainly organised
by ESR1 and Sp1 (activation module). A series of coherent type 2
motifs emanates from AR and p53 (repression module). Both motif
architectures may reduce the impact of transient noise in genetic
networks and may therefore govern stable activation or repression
of hTERT [21]. Although direct validation of individual motifs is
beyond the scope of this study, BIO reduced p53 binding at
hTERT, MYC, RELA, and ESR1 promoters in ChIP experiments,
suggesting coordinated functional regulation of transcriptional
interactions consistent with the proposed topology of the
repression module. The network also contains multiple potential
switch and feedback oscillator motifs, suggesting there is
substantial scope for dynamic network behaviour [21–23].
Indeed, several network components, including p53 and NFkB
are known to exhibit dynamic oscillations under certain conditions
[28,29]. Inter-transcription factor interactions may provide
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Figure 8. Whole-kinome RNAi screen of the hTERT promoter in A2780. (A) hTERT-luciferase was cotransfected with 50 nM siRNA in triplicate.
48 h post-transfection, luciferase assays were performed. 3 independent siRNA per target were assessed. Hit criterion was .2-fold change in
promoter activity by at least 2/3 siRNA. 235 hit IDs were analysed in MetaCore using the ‘‘direct interactions’’ algorithm limited to phosphorylation
interactions. Green arrows: positive regulation; red: negative regulation. Blue circles: siRNA repressed the hTERT promoter. Circle shading intensity
indicates fold change (minimum 2-fold). Average derived from all independent hit siRNA is shown. (B) Relative repression of the hTERT promoter by
siRNA against targets in the network model. Luciferase activities were calculated relative to control (non-specific) for each siRNA. Figure shows
mean6SEM derived from all independent hit siRNA for each target.
doi:10.1371/journal.pone.0006459.g008
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another mechanism for dynamic behaviour. Notably, GSK3
directly controls stability of several transcription factors [30]. An
interesting possibility is that GSK3 exerts a ‘‘compressor’’ effect
which fine-tunes the overall network steady state. Consistent with
this interpretation, expression of several transcription factors
varied dynamically over long term GSK3 inhibition.
Currently, the frequency of these fluctuations is unknown and
may even involve stochastic events. Therefore, other apparently
unaffected factors may also be regulated at different time points, or
their activities may be subject to dynamic changes independently
of expression, as would appear to be the case with Sp1. Overnight
BIO treatment had no effect on Sp1 levels at the hTERT promoter
and its expression was unaffected in the time course. However, 3
week treatments did increase Sp1 epitope at both the hTERT and
TP53 promoters, confirming that it participates in dynamic
regulation of hTERT and other network components.
Knowledge of other druggable target pathways affecting the
network may provide strategies to complement and/or stabilise
telomerase inhibition. To discover other candidate kinase targets
potentially affecting hTERT, we performed a whole kinome siRNA
screen using the hTERT reporter, revealing 235 kinase genes that
regulate promoter activity in A2780, of which at least 54
phosphorylate components of the network model. Key hubs were
GSK3 itself, p90-RSK, several PKC isoforms, PKA, and the JNK
and p38 MAP kinases. Future studies will determine their
functional involvement in regulation of telomerase by GSK3.
In summary, our results suggest computational and screening
approaches combined with appropriate focused validation efforts
may lead to a more nuanced understanding of telomerase gene
regulation. Our data lend support to the emerging prospect of
GSK3 inhibitor therapy of cancer, both from the standpoint of
telomerase inhibition and because of the rapid xenograft growth
reduction effect observed which may also involve additional effects
of GSK3 inhibition [31]. However, prolonged GSK3 inhibition
has complex network effects, at least in cancer cells. Therefore,
combinatorial regimens may be most appropriate. This finding
may also have implications for the use of single agent GSK3
inhibitors in the settings of bipolar disorder, Alzheimer’s disease
and diabetes in which long term treatment schedules are also
required. We have identified several markers of dynamic network
behaviour. Their examination in suitable model systems for these
disorders may also be advisable. Finally, GSK3 inhibition has been
proposed as a method to expand stem and progenitor cell pools.
Protocols involving telomerase positive progenitors should also
address telomere status.
Materials and Methods
Cell lines, plasmids, siRNA and inhibitors
Cells used were: 5637 bladder carcinoma, C33A cervical
carcinoma, A549 lung adenocarcinoma, and HCT116 colon
carcinoma cells, obtained from ATCC, and A2780 ovarian
adenocarcinoma cells, originally obtained from Dr RF Ozols
[32]. Reporter pGL3-hTERT contains the hTERT promoter
region -585/-9, relative to the translational start site. Plasmids
pCMV-mWnt3 and pCMV-mWnt5a were kindly provided by Dr.
Mejlinda Lako (Institute for Ageing and Health, Newcastle
University, UK). Human DVL2 and b-catenin expression vectors
were obtained from Origene (Rockville, MD). The whole kinome
siRNA library, non-specific siRNA and GSK3b-specific siRNA
(siRNA 42839: sense sequence 59-GGACAAGAGAUUUAA-
GAAUtt; siRNA 203: sense sequence 59-GGUGACAACAGUG-
GUGGCAtt) were obtained from Applied Biosystems (Warring-
ton, UK). The kinase inhibitor library was obtained from Biomol
International Ltd (UK). BIO, AR-A014418, TWS119, Roscov-
itine, and 1-MeBIO were obtained from EMD Biosciences
(Nottingham, UK).
Transfections and luciferase assay
All transfections were performed in quadruplicate using
lipofectamine according to the manufacturer’s instructions using
a 2:1 ratio reagent:DNA (Invitrogen, Paisley, UK). Under these
conditions, transfection efficiencies were found by pSV40-bGal
assay to be: HCT116, 51%; A549, 39%; A2780, 27%; 5637, 29%;
C33A, 28%. 250 ng hTERT reporter plasmid per well was
transfected in 96-well luminometer plates (Fisher Scientific UK,
Leicestershire, UK). 32 h post-transfection cells were exposed to
inhibitors for 16 h. In cotransfections, 250 ng expression vectors
or 50 nM siRNAs were included. 30 ng pSV40-Renilla luciferase
expression plasmid (Promega Ltd, Madison, WI) was included in
each well for normalisation. 48 h post-transfection, luciferase
activities were determined using dual luciferase assay reagents
according to the manufacturer’s instructions (Promega Ltd,
Madison, WI). All experiments were repeated at least 3 times.
MTT assay
Cells were seeded in quadruplicate wells and triplicate 96-well
plates 2 days prior to addition of inhibitor titrations. Cells were
exposed to inhibitors for 16 h then incubated for an additional 3–4
days prior to MTT assay (MTT supplied by Sigma (Dorset, UK)).
MTT reduction assays were performed using Softmax Pro 4.6
software (Molecular Devices Ltd., Wokingham, UK). All exper-
iments were repeated at least 3 times.
Western blotting
Protein extracts were prepared in passive lysis buffer (Promega
Ltd, Madison, WI). Protein concentrations were estimated at
OD595 using the BioRad protein assay (BioRad Laboratories Ltd,
Hemel Hempstead, UK). 20 mg protein for singleplex experi-
ments, or 1 mg protein for multiplex analysis, were separated by
SDS-PAGE, blotted onto PVDF filter (Millipore, Watford, UK)
and blocked overnight in PBS-T containing 5% non-fat dried
milk. All antibodies are listed in supporting file S1. For multiplex
analysis, membrane was separated into lanes using Immunetics’
miniblotter 28 dual apparatus (Web Scientific, UK). Primary
antibodies were detected with HRP-conjugated secondary. HRP
was detected using ECL HRP detection reagents (Amersham
Pharmacia, Buckinghamshire, U.K.). All experiments were
performed at least twice.
ChIP assays
DMSOorBIOtreated cellswereharvestedat 70%–80%confluence.
ChIP assays were performed following instructions of the kit supplier
(Millipore, Watford, UK). Cell layers were fixed in formaldehyde and
lysed in SDS buffer with protease inhibitors. Chromatin fragments of
500 bp-1 kb were generated by sonication using a Branson S25OD
sonifier (Branson Ultrasonics Corp., Danbury, CT). All antibodies are
listed in supporting file S1. Each assay included a no antibody control.
Each promoter was detected by Q-PCR in triplicate using Genetic
Research Instrumentation Opticon monitor equipment and software
(Essex,UK) and sybr green fluorophore. Promoter-specific primers used
were: hTERT, 59-CATTCGTGGTGCCCGGAGC and 59-GCCC-
CAGCGGAGAGAGGTCG or 59-GCGACCTGTAATCCTA-
AGTATT and 59-GGGTTGCTCAAGTTTGGATCTAA for p53
binding analysis; TP53, 59-GCACCAGGTCGGCGAGAATCC-
TGand59-CGTGGAAAGCACGCTCCCAGCC;ESR1, 59-CCAA-
TGTCAGGGCAAGGCAA and 59-GGAGCCTGCGGGTCC-
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GGTGAA;RELA, 59-AGTTCAACCACCCGGCCTCTand59-GA-
GGGTGGGTCCGCCGATTA; MYC, 59-GCTGCCCGGCT-
GAGTCTCCTCCC and 59-CCTCCCCACCTTCCCCACCCTC.
Optical read temperatureswere optimised to exclude primer dimers.All
ChIP experiments were performed at least 3 times. Q-PCR was
repeated twice for each experiment.
TRAP assay
The TRAPeze XL kit was used for TRAP assay according to
the manufacturer’s instructions (Millipore, Watford, UK). Cell
pellets were lysed in CHAPS lysis buffer and protein concentra-
tions estimated by Bio-Rad assay (BioRad Laboratories Ltd,
Hemel Hempstead, UK). 0.5 mg protein was mixed with
TRAPeze reaction mix containing TS primer, fluorescein labelled
RP primer, control template and sulforhodamine labelled control
K2 primer. Each assay included no-telomerase, no-Taq, and heat-
treated controls. Extension products were generated at 30C
followed by Q-PCR detection in triplicate using Chromo4
equipment and software (BioRad Laboratories Ltd, Hemel
Hempstead, UK). Total product generated was measured against
TR8 standards and normalised to the ROX internal control. All
experiments were performed three times and the TRAP assay was
repeated twice for each experiment.
TRF analysis
Telomere length assays were performed using the teloTAGGG
kit according to the manufacturer’s instructions (Roche Diagnos-
tics Ltd., West Sussex, UK). 1 mg genomic DNA from cell pellets
was digested with HinfI/RsaI. Digestion products were separated
by gel electrophoresis alongside DIG-labelled molecular weight
markers and blotted onto positively charged nylon membrane
(Roche Diagnostics Ltd., West Sussex, UK). Membranes were UV
cross-linked, baked at 120C and washed in 26SSC solution.
Hybridisation of the DIG-labelled telomeric probe was performed
using buffers and probe provided. Finally, membranes were
washed, probed with alkaline phosphatase conjugated anti-DIG
and exposed to the CDP-star substrate. All experiments were
performed at least twice.
Quantitative RT PCR
Q-PCR was performed in triplicate using Genetic Research
Instrumentation (Essex,UK)Opticonmonitor equipment and software.
Sybr greenwas used as fluorophore. The primers usedwere:RPS15, 59-
TTCCGCAAGTTCACCTACC and 59-CGGGCCGGCCAT-
GCTTTACG; hTERT 59-CTGCTGCGCACGTGGGAAGC and
59-GGACACCTGGCGGAAGGAG.Optical read temperatureswere
optimised to exclude primer dimers. All treatments were repeated three
times and Q-PCR was performed twice for each assay. Splice variant
PCRwas performedwith primers 59-GCCTGAGCTGTACTTTGT-
CAA and 59-GCCAAACAGCTTGTTCTCCATGTC and analysed
using an Agilent Bioanalyser 2100 and DNA-1000 assay chips (Agilent
Technologies, Santa Clara, CA).
Microarray processing
RNA from 3 independent treatments was labelled and amplified
using the two-colour microarray gene expression analysis protocol
(Agilent Technologies, Santa Clara, CA). Control cell RNA was
labelled with cyanine 3-CTP and BIO treated cell RNA labelled
with cyanine 5-CTP. 750 ng of cy-3 and cy-5 labelled, amplified
cRNA were mixed and hybridised in duplicate to 44 k Agilent
whole human genome microarrays, according to the manufactur-
ers instructions and incubated for 17 hrs at 60uC in a rotating
hybridisation oven. Arrays were washed on a magnetic stirrer
using Agilent wash buffers. Slides were scanned on an Agilent
DNA microarray scanner at 5 mm resolution, PMT at 100% and
10%. The extended dynamic range setting corrected for
saturation.
Microarray data analysis
Microarray data was processed in line with the Microarray
Gene Expression Data Society (http://www.mged.org/) to
standardize the presentation of microarray data. MIAME
compliant data have been deposited for public access in the Gene
Expression Omnibus (GEO) at http://www.ncbi.nlm.nih.gov/
geo/ with the accession number GSE14532. Data was extracted
using Agilent Feature Extraction software version 8.1 (Agilent
Technologies). Background-subtracted data for separated red and
green channels was imported into GeneSpring GX 7.3.1 (Agilent
Technologies, Santa Clara, CA) for normalisation and statistical
analysis. Intra-array normalisation was carried out using the 50th
percentile for each microarray. Significant differences in expres-
sion between DMSO control and BIO treated cells were
determined using Welch analysis of variance (ANOVA) assuming
normality, but not equal variances and Benjamini and Hochberg
false discovery rate multiple testing correction of 5%. IDs with.5-
fold intensity change, p,0.01 were selected for further analysis.
MetaCore network analysis
Differentially expressed genes from supporting file S2 were
analysed using the ‘‘transcription regulation’’ algorithm in
MetaCore from GeneGo Inc. (filters: positive and negative
interaction types; all mechanisms). All genes from the 10 most
significant returned networks were merged to an enriched list and
analysed using the ‘‘auto expand’’ algorithm (filters: positive and
negative interaction types; all mechanisms). A best fit transcrip-
tional network was identified by varying the network size. Edges
linking high-degree transcription factors with GSK3 were
identified using the ‘‘analyse network’’ algorithm (filters: positive
and negative interaction types, all mechanisms). For kinome-wide
RNAi analysis, edges linking hits with high-degree transcription
factors from the candidate pathway were identified using the
‘‘direct interactions’’ algorithm (filters: positive and negative
phosphorylation interaction types only, kinase and transcription
factor object-types only). Algorithms are described in [20]. All
interactions in MetaCore are manually compiled from full text
articles. All references are available on request.
Multiplex oligonucleotide binding assay
Consensus oligonucleotide binding assay was performed using
the protein/DNA array I kit from Panomics (Freemont, CA)
according to the manufacturers instructions. 10 mg nuclear
extracts prepared with Panomics nuclear extraction kit were
incubated with biotin labelled consensus oligonucleotide probe
mix. Bound probes were isolated on spin columns, denatured and
hybridised to nylon membrane containing a consensus transcrip-
tion factor binding sequence array. Membranes were washed in
hybridisation wash I and wash II then blocked using blocking
buffer supplied. Finally, membranes were incubated with strepta-
vidin-HRP, washed, and labelled probes were detected with
chemiluminescent detection reagents supplied.
Xenograft experiments
Animal studies were carried out under an appropriate United
Kingdom Home Office Project Licence and all work conformed to
UKCCR Guidelines for welfare of animals in experimental
neoplasia. 107 A2780 cells in PBS were injected subcutaneously
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into the right flank of CD1 nu/nu mice (Charles River). After 7 to
10 days when mean tumour diameter was ,0.5 cm (day 0),
animals were randomized in groups of 6. A stock solution of 2 mg/
ml BIO was prepared and diluted into PBS immediately before
injection. Mice were treated intraperitoneally with BIO at a dose
of 2 mg/kg on alternate days or at a dose of 6 mg/kg twice weekly
on days 1 and 4. Tumour volumes were estimated by calliper
measurements assuming spherical geometry (volume= d36p/6).
Densitometry
Densitometry was performed on telomere length experiments,
western blots and multiplex oligonucleotide binding experiments
using a BioRad GS-800 densitometer (BioRad Laboratories Ltd,
Hemel Hempstead, UK) and Quantity One software.
Statistical analysis
Statistical analysis of all experiments was performed by one way
ANOVA except hTERT expression in xenografts, which was
analysed by Mann-Witney U test.
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